I-SPY2-990 mRNA/RPPA Data Resource: RPPA component

The RPPA component of the I-SPY2-990 mRNA/RPPA Data Resource contains protein/phosphoprotein data from pre-treatment laser capture microdissected (LCM) tumor biopsies for 139 key signaling proteins/phosphoproteins in cancer for 736 patients from 8 arms of the neoadjuvant I-SPY2 TRIAL (NCT01042379) for aggressive early stage breast cancer [194 Control (Ctr); 63 veliparib/carboplatin (VC); 105 neratinib (N); 87 MK2206; 128 trebananib; 49 TDM1/pertuzumab(P); 43 H/P; and 67 pembrolizumab (pembro)]. This record also contains clinical data for these patients, including HR, HER2 and MP status, response (pCR or no pCR), and treatment arm. RPPA endpoints assayed are from hormone receptor (n=4), HER family (n=14), cell cycle/proliferation (n=20), immune (n=18), DNA repair deficiency (DDR; n=15), AKT/mTOR/PI3K (n=7), apoptosis/autophagy (n=10), IGF1R (n=6), TIE/ANG (n=4), growth/survival/metabolism (n=22) and RTK (n=19) pathways. For gene expresson data for all 736 patients with RPPA data, plus an additional 150 patients for a total 987 patients from 10 arms of I-SPY2 (mRNA component of the I-SPY2-990 Data Resource), see the companion GEO record/subseries GSE194040. Reverse phase protein array (RPPA) array run on isolates from pre-treatment breast cancer biopsy samples that were first LCM-enriched for epithelial cells. The sample characteristics and their values represent: HER2: the status of the HER2 gene. 1 = positive; 0 = negative. HR: the status of hormone (estrogen and progesterone) receptors. 1 = positive; 0 = negative. pCR: the status of a pathological complete response (pCR). 1 = complete response; 0 = failed complete response Arm: arm of the trial per patient, detailing treatment during taxol-phase of protocol: Paclitaxil (Control arm: HER2- subset); Paclitaxil + Trastuzumab (Control arm: HER2+ subset); Paclitaxel + ABT-888 (veliparib) + Carboplatin; Paclitaxel + AMG-386 (AMG-386 arm: HER2- subset); Paclitaxel + AMG-386 + Trastuzumab (AMG-386 arm: HER2+ subset); Paclitaxel + MK-2206 (MK-2206 arm: HER2- subset); Paclitaxel + MK-2206 + Trastuzumab (MK-2206 arm: HER2+ subset); Paclitaxel + Neratinib; Paclitaxel + Pembrolizumab; Paclitaxel + Pertuzumab + Trastuzumab; or T-DM1 + Pertuzumab. All patients also received subsequent doxorubicin + cyclophosphamide. Arm (short name): abbreviated name of treatment arm in the trial per patient (n=8 arms) - Control, VC, AMG-386, MK-2206, N, Pembro, Pertuzumab, TDM1/P RPPA Array: Platform Array version. Key to convert from raw to normalized data.